Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:07:00 EST Sun 16 Feb 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:AZN
- ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS -
https://www.astrazeneca.com
11:07:00 EST
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
AZN
- Q
0.2
73.59
·
74.35
3.6
73.58
-0.878
-1.2
5,783.7
425,163
32,986
74.335
74.58
73.4501
87.67 61.77
19:52:35
11:10
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Up
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 32986
More trades...
Time ET
Ex
Price
Change
Volume
19:52:35
Q
73.59
-0.86
14
19:48:49
Q
73.60
-0.85
27
19:46:41
Q
73.59
-0.86
5
19:07:07
Q
73.60
-0.85
40
18:29:15
Q
73.5325
-0.9175
1
18:29:15
Q
73.5325
-0.9175
1
18:25:34
Q
73.503
-0.947
33
18:13:49
Q
73.84
-0.61
22
17:43:37
Q
73.93
-0.52
1
17:43:27
Q
73.52
-0.93
1
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-02-14 11:10
U:AZN
News Release
200
IMFINZI(TM) (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
2025-02-06 07:00
U:AZN
News Release
200
AstraZeneca's Full Year and Q4 2024 results
2025-01-27 18:00
U:AZN
News Release
200
ENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
2025-01-23 14:31
U:AZN
News Release
200
AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery
2025-01-22 08:30
U:AZN
News Release
200
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
2025-01-17 17:35
U:AZN
News Release
200
DATROWAY(TM) (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2025-01-17 07:00
U:AZN
News Release
200
CALQUENCE(TM) (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
2025-01-13 07:00
U:AZN
News Release
200
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2024-12-26 09:00
U:AZN
News Release
200
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
2024-12-18 09:05
U:AZN
News Release
200
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform
2024-12-11 10:15
U:AZN
News Release
200
LYNPARZA(TM) (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
2024-12-09 07:00
U:AZN
News Release
200
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2024-12-08 11:00
U:AZN
News Release
200
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
2024-12-06 07:00
U:AZN
News Release
200
IMFINZI(TM) (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer
2024-12-05 07:13
U:AZN
News Release
200
IMFINZI(TM) (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
2024-11-25 07:00
U:AZN
News Release
200
TRUQAP(TM) (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
2024-11-20 07:30
U:AZN
News Release
200
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
2024-11-18 16:01
U:AZN
News Release
200
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
2024-11-12 07:00
U:AZN
News Release
200
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
2024-11-12 07:00
U:AZN
News Release
200
AstraZeneca's 9M and Q3 2024 results